Report: ‘Pay-to-delay’ agreements for 20 drugs cost consumers $98B

Brand name drug companies made an estimated $98 billion in total sales of 20 drugs while the generic versions of those same drugs were delayed under what’s become know as “pay-to-delay” settlements, according to a report by MassPirg and Community Catalyst...